Circulating endothelial cells in essential thrombocythemia and polycythemia vera: Correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers

International Journal of Hematology

Volumn 91, Issue 5, 2010, Pages 792-798

  Treliński, Jacek ^a   Wierzbowska, Agnieszka ^a   Krawczyńska, Anna ^a   Sakowicz, Agata ^a   Pietrucha, Tadeusz ^a   Smolewski, Piotr ^a   Robak, Tadeusz ^a   Chojnowski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; Circulating endothelial cells; Essential thrombocythemia; JAK2 V617F mutation; Polycythemia vera

Indexed keywords

ANGIOGENIC FACTOR; BLOOD CLOTTING FACTOR; JANUS KINASE 2; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; PLACENTA PROTEIN; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; MUTATIONAL ANALYSIS; POLYCYTHEMIA VERA; PROTEIN BLOOD LEVEL; THROMBOCYTHEMIA; THROMBOSIS; BLOOD; BLOOD CLOTTING; GENETICS; MIDDLE AGED; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ADULT; AGED; BLOOD COAGULATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; POLYCYTHEMIA VERA; PREGNANCY PROTEINS; THROMBOCYTHEMIA, ESSENTIAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77954532667     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0596-7     Document Type: Article

References (45)

1. A Alonci A Allegra G Bellomo G Penna A D'Angelo E Quartarone, et al. 2008 Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases Hematol Oncol 26 235 239 10.1002/hon.865 1:STN:280:DC%2BD1cjnvFyhsw%3D%3D 18504767
2. M Medinger R Skoda A Gratwohl A Theocharides A Buser D Heim, et al. 2009 Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status Br J Haematol 146 150 157 10.1111/j.1365-2141.2009. 07726.x 1:CAS:528:DC%2BD1MXps1Oit7g%3D 19466975
3. C Musolino L Calabro' G Bellomo F Martello B Loteta C Pezzano, et al. 2002 Soluble angiogenic factors: implications for chronic myeloproliferative disorders Am J Hematol 69 159 163 10.1002/ajh.10020 1:CAS:528: DC%2BD38Xit1ejsLc%3D 11891801 (Pubitemid 34177468)
4. K Panteli M Bai E Hatzimichael N Zagorianakou NJ Agnantis K Bourantas 2007 Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases Hematology 12 481 487 10.1080/10245330701554664 1:CAS:528:DC%2BD2sXht1aktrbN 17852434 (Pubitemid 350048055)
5. A Wierzbowska T Robak A Krawczyńska A Wrzesień-Kuś A Pluta B Cebula, et al. 2005 Circulating endothelial cells in patients with acute myeloid leukemia Eur J Haematol 75 492 497 10.1111/j.1600-0609.2005.00549. x 16313261 (Pubitemid 41693370)
6. J Gora-Tybor K Jamroziak A Szmigielska-Kaplon A Krawczynska E Lech-Maranda A Wierzbowska, et al. 2009 Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia Leuk Lymphoma 50 62 67 10.1080/10428190802549883 1:CAS:528: DC%2BD1MXhtVCrt7o%3D 19125384
7. A Tefferi JW Vardiman 2008 Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms Leukemia 22 14 22 10.1038/sj.leu.2404955 1:CAS:528:DC%2BD1cXmsV2jtA%3D%3D 17882280
8. RA Mesa CA Hanson CY Li SY Yoon SV Rajkumar G Schroeder A Tefferi 2002 Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia Blood 99 4131 4137 10.1182/blood.V99.11.4131 1:CAS:528:DC%2BD38XktFyrsbg%3D 12010817 (Pubitemid 35332057)
9. T Wróbel G Mazur P Surowiak D Wołowiec M Jeleń K Kuliczkowski 2003 Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD) Pathol Oncol Res 9 170 173 10.1007/BF03033732 14530810 (Pubitemid 37429496)
10. WT Bellamy L Richter Y Frutiger TM Grogan 1999 Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies Cancer Res 59 728 733 1:CAS:528:DyaK1MXhtFSitr8%3D 9973224
11. S Dias K Hattori B Heissig Z Zhu Y Wu L Witte, et al. 2001 Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias Proc Natl Acad Sci USA 98 10857 10862 10.1073/pnas.191117498 1:CAS:528:DC%2BD3MXntVGmsbw%3D 11553814 (Pubitemid 32878709)
12. S Monestiroli P Mancuso A Burlini G Pruneri C Dell'Agnola A Gobbi, et al. 2001 Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma Cancer Res 61 4341 4344 1:CAS:528:DC%2BD3MXktlSqu74%3D 11389057
13. P Mancuso A Burlini G Pruneri A Goldhirsch G Martinelli F Bertolini 2001 Resting and activated endothelial cells are increased in the peripheral blood of cancer patients Blood 97 3658 3661 10.1182/blood.V97.11.3658 1:CAS:528:DC%2BD3MXktFOku7k%3D 11369666
14. LV Beerepoot N Mehra JS Vermaat BA Zonnenberg MF Gebbink EE Voest 2004 Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients Ann Oncol 15 139 145 10.1093/annonc/ mdh017 1:STN:280:DC%2BD3srps1Kltg%3D%3D 14679134 (Pubitemid 38139616)
15. Y Lin DJ Weisdorf A Solovey RP Hebbel 2000 Origins of circulating endothelial cells and endothelial outgrowth from blood J Clin Invest 105 71 77 10.1172/JCI8071 1:CAS:528:DC%2BD3cXislSrtg%3D%3D 10619863
16. H Zhang V Vakil M Braunstein EL Smith J Maroney L Chen, et al. 2005 Endothelial progenitor cells in multiple myeloma: implications and significance Blood 105 3286 3294 10.1182/blood-2004-06-2101 1:CAS:528:DC%2BD2MXjtlSlsro%3D 15618473
17. MA Elliott A Tefferi 2005 Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia Br J Haematol 128 275 290 10.1111/j.1365-2141.2004.05277.x 1:STN:280:DC%2BD2M%2FktVSntg%3D%3D 15667529 (Pubitemid 40216149)
18. AP Wolanskyj SM Schwager RF McClure DR Larson A Tefferi 2006 Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors Mayo Clin Proc 81 159 166 10.4065/81.2.159 16471068
19. A Carobbio G Finazzi V Guerini O Spinelli F Delaini R Marchioli, et al. 2007 Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status Blood 109 2310 2313 10.1182/blood-2006-09-046342 1:CAS:528:DC%2BD2sXnslygsr0%3D 17110452 (Pubitemid 46425868)
20. AM Vannucchi E Antonioli P Guglielmelli A Rambaldi G Barosi R Marchioli, et al. 2007 Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia Blood 110 840 846 10.1182/blood-2006-12-064287 1:CAS:528:DC%2BD2sXos1CqsL4%3D 17379742 (Pubitemid 47267419)
21. AM Vannucchi E Antonioli P Guglielmelli G Longo A Pancrazzi V Ponziani MPD Research Consortium, et al. 2007 Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden Leukemia 21 1952 1959 10.1038/sj.leu.2404854 1:CAS:528:DC%2BD2sXptlSrsb0%3D 17625606 (Pubitemid 47299969)
22. RE Banks MA Forbes SE Kinsey A Stanley E Ingham C Walters, et al. 1998 Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology Br J Cancer 77 956 964 1:CAS:528:DyaK1cXitlyrtrY%3D 9528841
23. A Weltermann M Wolzt K Petersmann C Czerni U Graselli K Lechner, et al. 1999 Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo Arterioscler Thromb Vasc Biol 19 1757 1760 1:CAS:528:DyaK1MXkvV2ksr0%3D 10397695
24. EJ Baxter LM Scott PJ Campbell C East N Fourouclas S Swanton, et al. 2005 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054 1061 1:CAS:528:DC%2BD2MXisFGrs7g%3D 15781101
25. A Cortelezzi NS Fracchiolla LM Mazzeo I Silvestris M Pomati F Somalvico, et al. 2005 Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes Leuk Lymphoma 46 1345 1351 10.1080/10428190500144235 1:CAS:528:DC%2BD2MXpslyktb0%3D 16109613 (Pubitemid 41269302)
26. P Mancuso M Colleoni A Calleri L Orlando P Maisonneuve G Pruneri, et al. 2006 Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy Blood 108 452 459 10.1182/blood-2005-11-4570 1:CAS:528:DC%2BD28XntFeht78%3D 16543470 (Pubitemid 44061341)
27. E Boveri F Passamonti E Rumi D Pietra C Elena L Arcaini, et al. 2008 Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations Br J Haematol 140 162 168 18028479
28. A Falanga M Marchetti V Evangelista A Vignoli M Licini M Balicco, et al. 2000 Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera Blood 96 4261 4266 1:CAS:528:DC%2BD3cXosl2ht7Y%3D 11110700
29. MC Trappenburg M van Schilfgaarde M Marchetti HM Spronk H ten Cate A Leyte, et al. 2009 Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia Haematologica 94 911 918 10.3324/haematol.13774 1:CAS:528:DC%2BD1MXhtVGitr3E 19508974
30. J Treliński M Tybura P Smolewski T Robak K Chojnowski 2009 The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia Blood Coagul Fibrinolysis 20 646 651 10.1097/MBC.0b013e32832f6c5b 19741509
31. A Falanga M Marchetti A Vignoli D Balducci T Barbui 2005 Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera Exp Hematol 33 523 530 10.1016/j.exphem.2005.01.015 1:CAS:528:DC%2BD2MXjsFKhsrY%3D 15850829 (Pubitemid 40592168)
32. C Musolino A Alonci G Bellomo O Tringali G Spatari C Quartarone, et al. 2000 Myeloproliferative disease: markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera Hematology 4 397 402 1:CAS:528:DC%2BD3cXnt1Kgu7k%3D 11399581
33. D Rość E Kremplewska-Nalezyta G Gadomska A Kowalewska E Buczkowska 2006 Thrombinogenesis in chronic myeloproliferative syndromes Pol Merkur Lekarski 20 717 720 17007278
34. B Robertson C Urquhart I Ford J Townend HG Watson MA Vickers, et al. 2007 Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies J Thromb Haemost 5 1679 1685 10.1111/j.1538-7836.2007.02626.x 1:CAS:528:DC%2BD2sXhtVent73P 17596137 (Pubitemid 47091411)
35. IJ Dahabreh K Zoi S Giannouli C Zoi D Loukopoulos M Voulgarelis 2009 Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia Leuk Res. 33 67 73 10.1016/j.leukres.2008. 06.006 1:CAS:528:DC%2BD1cXhtlWltLjK 18632151
36. F Lussana S Caberlon C Pagani PW Kamphuisen HR Büller M Cattaneo 2009 Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review Thromb Res 124 409 417 10.1016/j.thromres.2009.02.004 1:CAS:528:DC%2BD1MXhtVOju77K 19299003
37. E Arellano-Rodrigo A Alvarez-Larrán JC Reverter N Villamor D Colomer F Cervantes 2006 Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status Haematologica 91 169 175 1:CAS:528:DC%2BD28XisFWrs7Y%3D 16461300
38. V De Stefano A Fiorini E Rossi T Za G Farina P Chiusolo S Sica G Leone 2007 Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders J Thromb Haemost 5 708 714 10.1111/j.1538-7836.2007.02424.x 17263783 (Pubitemid 46563568)
39. A Carobbio G Finazzi E Antonioli, et al. 2009 JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera Exp Hematol 37 1016 1021 10.1016/j.exphem.2009.06.006 1:CAS:528: DC%2BD1MXhtVSjsr%2FI 19559071
40. F Palandri E Ottaviani F Salmi, et al. 2009 JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients Leuk Lymphoma 50 247 253 10.1080/10428190802688152 1:CAS:528:DC%2BD1MXltVaiu74%3D 19235016
41. N Ferrara 1999 Molecular and biological properties of vascular endothelial growth factor J Mol Med 77 527 543 10.1007/s001099900019 1:CAS:528:DyaK1MXmsFOiurY%3D 10494799 (Pubitemid 29426311)
42. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676 10.1038/nm0603-669 1:CAS:528:DC%2BD3sXktFOnur4%3D 12778165 (Pubitemid 36749215)
43. RR Cacciola E Di Francesco R Giustolisi E Cacciola 2002 Elevated serum vascular endothelial growth factor levels in patients with polycythemia vera and thrombotic complications Haematologica 87 774 775 1:CAS:528: DC%2BD38XmsVKktL8%3D 12091131
44. P Carmeliet L Moons A Luttun V Vincenti V Compernolle M De Mol, et al. 2001 Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions Nat Med 7 575 583 10.1038/87904 1:CAS:528:DC%2BD3MXjsVakurc%3D 11329059 (Pubitemid 32448325)
45. JE Park HH Chen J Winer KA Houck N Ferrara 1994 Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR J Biol Chem 269 25646 25654 1:CAS:528:DyaK2cXlvFKksbs%3D 7929268